Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken
Aandeel

VIVORYON THERAPEUTICS N.V. NL00150002Q7

Laatste koers (eur)

2,205

  • Verschil

    +0,015 +0,68%

  • Volume

    69.446 Gem. (3M) 180,4K

  • Bied

    -  

  • Laat

    -  
+ Toevoegen aan watchlist

Vivoryon in 2024: Overname, Deal of Down the Drain?

2.637 Posts
Pagina: «« 1 ... 42 43 44 45 46 ... 132 »» | Laatste | Omlaag ↓
  6. Strateeg 21 mei 2024 11:07

    • Strateeg

      Lid sinds: 15 mrt 2019

      Laatste bezoek: 08 nov 2024

    • Aanbevelingen

      Ontvangen: 218

      Gegeven: 1

    •    Aantal posts: 753

    en toch denk ik dat de knal van Euro 8,-- in 1 dag naar penny stock een overdreven reactie was.
    De meningen zijn vooral negatief op dit aandeel, een klein lichtpuntje kan al voor een enorme stijging zorgen.
    We gaan het donderdag zien.
  7. Robb 21 mei 2024 12:01

    • Robb

      Lid sinds: 24 mrt 2014

      Laatste bezoek: 08 nov 2024

    • Aanbevelingen

      Ontvangen: 193

      Gegeven: 9

    •    Aantal posts: 1.615

    quote:

    Strateeg schreef op 21 mei 2024 11:07:

    en toch denk ik dat de knal van Euro 8,-- in 1 dag naar penny stock een overdreven reactie was.
    De meningen zijn vooral negatief op dit aandeel, een klein lichtpuntje kan al voor een enorme stijging zorgen.
    We gaan het donderdag zien.
    mee eens
  8. forum rang 10 DeZwarteRidder 21 mei 2024 12:15

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 10 nov 2024

    • Aanbevelingen

      Ontvangen: 23117

      Gegeven: 10250

    •    Aantal posts: 100.524

    quote:

    Strateeg schreef op 21 mei 2024 11:07:

    en toch denk ik dat de knal van Euro 8,-- in 1 dag naar penny stock een overdreven reactie was.
    De meningen zijn vooral negatief op dit aandeel, een klein lichtpuntje kan al voor een enorme stijging zorgen.
    We gaan het donderdag zien.
    Donderdag wordt een teleurstelling.
  9. forum rang 4 Rechterzijde 22 mei 2024 11:51

    • Rechterzijde

      Lid sinds: 30 mrt 2020

      Laatste bezoek: 10 nov 2024

    • Aanbevelingen

      Ontvangen: 767

      Gegeven: 2473

    •    Aantal posts: 1.286

    quote:

    Strateeg schreef op 21 mei 2024 11:07:

    en toch denk ik dat de knal van Euro 8,-- in 1 dag naar penny stock een overdreven reactie was.
    De meningen zijn vooral negatief op dit aandeel, een klein lichtpuntje kan al voor een enorme stijging zorgen.
    We gaan het donderdag zien.
    Zeker, ik ben gisteren ingestapt met een bescheiden aantal aandelen. Die gaan op de plank.
  12. Robb 22 mei 2024 14:54

    • Robb

      Lid sinds: 24 mrt 2014

      Laatste bezoek: 08 nov 2024

    • Aanbevelingen

      Ontvangen: 193

      Gegeven: 9

    •    Aantal posts: 1.615

    quote:

    Rechterzijde schreef op 22 mei 2024 11:51:

    [...]

    Zeker, ik ben gisteren ingestapt met een bescheiden aantal aandelen. Die gaan op de plank.
    Ik doe mee.
  14. forum rang 10 DeZwarteRidder 23 mei 2024 07:15

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 10 nov 2024

    • Aanbevelingen

      Ontvangen: 23117

      Gegeven: 10250

    •    Aantal posts: 100.524

    Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease

    Additional kidney function analyses strongly support Vivoryon’s shift in strategic focus to inflammatory and fibrotic diseases, and are a further step towards securing Company’s future

    Varoglutamstat`s beneficial effect of improving kidney function, as demonstrated by an increase of estimated glomerular filtration rate (eGFR), confirmed by various sensitivity and subgroup analyses

    A significant and dose dependent reduction of the pyroglutamated version of CCL2 (pE-CCL2) in serum demonstrates effectiveness of varoglutamstat in inhibiting systemic intracellular QPCT/L and strongly supports an anti-inflammatory effect

    Alzheimer’s disease: No consistent effect on cognition could be shown in a subgroup of VIVIAD participants with higher drug exposure; VIVA-MIND topline results available end 2024 to inform next steps in AD

    Halle (Saale) / Munich, Germany, May 23, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced financial results for the first quarter of 2024, ending March 31, 2024, and provides a corporate update.

    “Vivoryon has now achieved proof of concept for varoglutamstat and validated the mechanism of action of QPCT/L inhibition. While the results in early AD were not what we had hoped for, we are excited about the promising effect of varoglutamstat on the pre-specified endpoint of kidney function given the established role of pro-inflammatory cytokines and peptides in driving the progression of kidney disease. In the past weeks, our team, which remains highly dedicated to driving our strategic shift and transformation, has continued to delve into the data on kidney function and we are pleased to see consistent results. We have observed robust and meaningful improvements in eGFR in patients treated with varoglutamstat compared to placebo across a range of different methods assessing eGFR. Effect sizes in favor of varoglutamstat were confirmed in patients with risk factors for CKD including diabetes and hypertension and were observed consistently across the range of eGFR baseline impairment levels in the study. We are now working on crystallizing our strategy and positioning in the kidney disease market and establishing potential clinical development plans for varoglutamstat in both large indications, such as CKD, and in certain rare diseases that impact kidney function,” said Frank Weber, MD, CEO of Vivoryon.

    Q1 2024 and Post-Period Updates

    Strategic shift towards a focus on inflammatory and fibrotic diseases:

    Following the announcement on March 4, 2024, that the VIVIAD Phase 2b study did not achieve its primary and key secondary endpoints in early AD and the subsequent results showing a significant positive effect of varoglutamstat on kidney function, Vivoryon announced on April 24, 2024, a strategic shift towards a focus on inflammatory and fibrotic diseases. Key priorities now include: exploring varoglutamstat’s potential in inflammatory and fibrotic disorders, including of the kidney; concluding VIVIAD Phase 2b clinical study program and in-depth analysis; discontinuing VIVA-MIND clinical Phase 2 study with varoglutamstat in the U.S. in early AD in the second half of 2024; leveraging the data from VIVA-MIND to inform next steps in AD; and continuing to actively pursue potential business development and financing opportunities.

    Varoglutamstat – kidney disease:

    QPCT/L inhibition has shown robust evidence of benefits in animal models of inflammatory and fibrotic disorders such as glomerulonephritis and non-alcoholic steatohepatitis (NASH). The VIVIAD protocol prospectively specified measurement of kidney function by estimated glomerular filtration rate (eGFR), a primary endpoint in many development programs of kidney disorders, and additional biomarkers, in order to further investigate this potential activity.
    Varoglutamstat 600mg BID increased eGFR over the treatment period up to 96 weeks in patients with early AD, indicating a potential benefit of varoglutamstat on kidney function.
    Further sensitivity and subgroup analysis has shown this effect is observed across the range of eGFR levels at baseline in the study, and when assessed using a set of diverse and validated methods for calculating kidney function.
    Additionally, the Company has explored the effect of varoglutamstat on levels of pyroglu-CCL2 (pE-CCL2), a pro-inflammatory cytokine. Persistent, low grade inflammation is considered a hallmark feature of chronic kidney disease (CKD). Results showed a significant and dose-dependent reduction in pE-CCL2 in the serum of VIVIAD patients following treatment with varoglutamstat. This demonstrates the effectiveness of varoglutamstat in inhibiting systemic intracellular QPCT/L and strongly supports an anti-inflammatory effect.
    Vivoryon is evaluating a clinical development path, as well as business development and financing opportunities, to further explore the potential of varoglutamstat and QPCT/L inhibitors in kidney disease in both large indications, such as CKD, and in certain rare diseases that impact kidney function, such as Alport Syndrome.
  15. forum rang 10 DeZwarteRidder 23 mei 2024 07:15

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 10 nov 2024

    • Aanbevelingen

      Ontvangen: 23117

      Gegeven: 10250

    •    Aantal posts: 100.524

    Varoglutamstat – early Alzheimer’s disease (AD):

    In recent weeks Vivoryon has continued its in-depth analysis of the VIVIAD data, following the March 4, 2024, and April 24, 2024, disclosures. While these analyses remain ongoing, findings to date continue to confirm there is no consistent effect of varoglutamstat up to 600mg BID on cognition and function, including in high exposure patients. Data from VIVA-MIND, anticipated by the end of 2024, is expected to contribute to the overall dataset informing varoglutamstat’s development strategy in AD.

    Early-Stage Pipeline

    Vivoryon’s main focus is on its clinical-stage activities, however it will continue to explore pre-clinical QPCT/L inhibitors for use in inflammatory and fibrotic disorders and other indications such as oncology and CNS as well as pre-clinical meprin inhibitors, in particular for fibrotic disorders, and QPCT/L inhibitors with good blood brain barrier penetration. The Company’s antibody program, PBD-C06, will remain active as a candidate for further potential partnering opportunities.

    Corporate Development Updates

    In March 2024, Kugan Sathiyanandarajah and Professor Dr. Morten Asser Karsdal stepped down from Vivoryon’s Board of Directors. They had been appointed as Non-Executive Directors in June 2023.
    In March 2024, Anne Doering, CFA, assumed the role of Chief Financial Officer (CFO) of Vivoryon, following her previous position as Chief Strategy & Investor Relations Officer.
    In May 2024, Vivoryon announced it will hold its 2024 Annual General Meeting on Friday, June 21, 2024, at 1:00 p.m. (CEST) in Amsterdam, the Netherlands. The full agenda and all relevant documents are available on the Company’s website (https://www.vivoryon.com/2024-annual-general-meeting/).

    Financial Results for the First Quarter of 2024

    Revenues were zero in the three months ended March 31, 2024, as well as in the three months ended March 31, 2023.

    Research and development expenses increased by EUR 4.3 million to EUR 7.4 million in the three months ended March 31, 2024, compared to EUR 3.1 million in the three months ended March 31, 2023. This increase was largely attributable to the increase in clinical development costs from the VIVIAD and VIVA-MIND studies.

    General and administrative expenses were EUR 2.1 million in the three months ended March 31, 2024, compared to EUR 1.9 million in the three months ended March 31, 2023. The increase of EUR 0.2 million was largely attributable to higher expenses for share-based payments as well as legal and consulting fees.

    Net loss for the three months ended March 31, 2024, was EUR 9.3 million, compared to EUR 5.1 million for the three months ended March 31, 2023.

    The Company held EUR 22.0 million in cash and cash equivalents as of March 31, 2024, compared to EUR 28.6 million, which includes cash and cash equivalents and financial assets, as of December 31, 2023.

    Outlook & Financial Guidance

    As published on April 24, 2024, the Company expects, on the basis of its most recent financial and business plan, that its existing cash and cash equivalents will be sufficient to fund its operating plans, excluding any additional financings, into the second quarter of 2025.

    This cash runway guidance reflects the shift in focus of research and development resources towards inflammatory and fibrotic disorders, such as of the kidney, and an overall reduction in cash utilization including the ramp down of spending on VIVIAD as it approaches its conclusion, the discontinuation of VIVA-MIND, the discontinuation of VIVALONG preparation activities given the developments of VIVIAD and VIVA-MIND, as well as the streamlining of manufacturing costs and programs for API development.

    The viability of the Company beyond the second quarter of 2025 is dependent on its ability to raise additional funds to finance its operations which also depends on the success of its research and development activities such as those focusing on exploring opportunities in kidney disease.
  17. forum rang 10 DeZwarteRidder 23 mei 2024 07:23

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 10 nov 2024

    • Aanbevelingen

      Ontvangen: 23117

      Gegeven: 10250

    •    Aantal posts: 100.524

    Primary analysis of change of estimated glomerular filtration rate (eGFR, slope analysis including all measurement timepoints during treatment):
    Annualized change of eGFR* P-Value Annualized Change of eGFR* P-Value
    Formula (creatinine) MDRD CKD-EPI 2021
    Placebo -1.51 -0.75
    Varoglutamstat +1.92 +1.44
    Treatment Effect (?) 3.43 p=0.0002 2.19 p=0.0015

    * mL/min/1.73m2/year

    Sensitivity analysis of estimated glomerular filtration (eGFR) rate using Cystatin C and Creatinine (remeasured on Atellica® platform) CKD-EPI 2021 formula at baseline, week 24 and week 48:
    Cystatin C Cystatin C and Creatinine Creatinine
    Week 24 Week 48 Week 24 Week 48 Week 24 Week 48
    Placebo
    (eGFR mL/min) 73.88 71.39 84.15 82.07 89.74 88.74
    Varoglutamstat
    (eGFR mL/min) 78.15 80.88 88.91 91.21 93.33 93.98
    Treatment Effect* (?) 4.27 9.49 4.76 9.14 3.59 5.24
    P-Value 0.0186 <0.0001 0.0041 <0.0001 0.0019 0.0003
  18. forum rang 10 DeZwarteRidder 23 mei 2024 07:25

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 10 nov 2024

    • Aanbevelingen

      Ontvangen: 23117

      Gegeven: 10250

    •    Aantal posts: 100.524

    quote:

    DeZwarteRidder schreef op 23 mei 2024 07:23:

    Primary analysis of change of estimated glomerular filtration rate (eGFR, slope analysis including all measurement timepoints during treatment):
    Annualized change of eGFR* P-Value Annualized Change of eGFR* P-Value
    Formula (creatinine) MDRD CKD-EPI 2021
    Placebo -1.51 -0.75
    Varoglutamstat +1.92 +1.44
    Treatment Effect (?) 3.43 p=0.0002 2.19 p=0.0015

    * mL/min/1.73m2/year

    Sensitivity analysis of estimated glomerular filtration (eGFR) rate using Cystatin C and Creatinine (remeasured on Atellica® platform) CKD-EPI 2021 formula at baseline, week 24 and week 48:
    Cystatin C Cystatin C and Creatinine Creatinine
    Week 24 Week 48 Week 24 Week 48 Week 24 Week 48
    Placebo
    (eGFR mL/min) 73.88 71.39 84.15 82.07 89.74 88.74
    Varoglutamstat
    (eGFR mL/min) 78.15 80.88 88.91 91.21 93.33 93.98
    Treatment Effect* (?) 4.27 9.49 4.76 9.14 3.59 5.24
    P-Value 0.0186 <0.0001 0.0041 <0.0001 0.0019 0.0003
    NB: ik zie weinig effect van Varoglutamstat.
  19. forum rang 10 DeZwarteRidder 23 mei 2024 07:30

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 10 nov 2024

    • Aanbevelingen

      Ontvangen: 23117

      Gegeven: 10250

    •    Aantal posts: 100.524

    Q1 2024 and Post-Period Updates

    Strategic shift towards a focus on inflammatory and fibrotic diseases:

    Following the announcement on March 4, 2024, that the VIVIAD Phase 2b study did not achieve its primary and key secondary endpoints in early AD and the subsequent results showing a significant positive effect of varoglutamstat on kidney function, Vivoryon announced on April 24, 2024, a strategic shift towards a focus on inflammatory and fibrotic diseases. Key priorities now include: exploring varoglutamstat’s potential in inflammatory and fibrotic disorders, including of the kidney; concluding VIVIAD Phase 2b clinical study program and in-depth analysis; discontinuing VIVA-MIND clinical Phase 2 study with varoglutamstat in the U.S. in early AD in the second half of 2024; leveraging the data from VIVA-MIND to inform next steps in AD; and continuing to actively pursue potential business development and financing opportunities.

    Varoglutamstat – kidney disease:

    QPCT/L inhibition has shown robust evidence of benefits in animal models of inflammatory and fibrotic disorders such as glomerulonephritis and non-alcoholic steatohepatitis (NASH). The VIVIAD protocol prospectively specified measurement of kidney function by estimated glomerular filtration rate (eGFR), a primary endpoint in many development programs of kidney disorders, and additional biomarkers, in order to further investigate this potential activity.
    Varoglutamstat 600mg BID increased eGFR over the treatment period up to 96 weeks in patients with early AD, indicating a potential benefit of varoglutamstat on kidney function.
    Further sensitivity and subgroup analysis has shown this effect is observed across the range of eGFR levels at baseline in the study, and when assessed using a set of diverse and validated methods for calculating kidney function.
    Additionally, the Company has explored the effect of varoglutamstat on levels of pyroglu-CCL2 (pE-CCL2), a pro-inflammatory cytokine. Persistent, low grade inflammation is considered a hallmark feature of chronic kidney disease (CKD). Results showed a significant and dose-dependent reduction in pE-CCL2 in the serum of VIVIAD patients following treatment with varoglutamstat. This demonstrates the effectiveness of varoglutamstat in inhibiting systemic intracellular QPCT/L and strongly supports an anti-inflammatory effect.
    Vivoryon is evaluating a clinical development path, as well as business development and financing opportunities, to further explore the potential of varoglutamstat and QPCT/L inhibitors in kidney disease in both large indications, such as CKD, and in certain rare diseases that impact kidney function, such as Alport Syndrome.
  20. forum rang 10 voda 23 mei 2024 07:56

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 10 nov 2024

    • Aanbevelingen

      Ontvangen: 89139

      Gegeven: 22125

    •    Aantal posts: 377.176

    Vivoryon verlegt focus op nierziekte
    23-mei-2024 07:49

    Na falen bij Alzheimer-middel.

    (ABM FN-Dow Jones) Vivoryon is optimistisch over de potentie van zijn middel varoglutamstat als mogelijk geneesmiddel bij nierziekte en richt zich daarom nu op ontstekings- en fibrotische aandoeningen, in plaats van op Alzheimer. Dat maakte het bedrijf donderdag bekend bij zijn eerstekwartaalcijfers.

    "De resultaten bij vroege Alzheimer waren niet waar we op hoopten, maar we zijn enthousiast over het veelbelovende effect van varuglutamstat op de nierfunctie", stelde CEO Frank Weber. "Vivoryon heeft een proof-of-concept bereikt voor varoglutamstat en het werkingsmechanisme gevalideerd rond inhibitie van QPCT/L", stelde het bedrijf. Dit zou wijzen op een ontstekingsremmende werking.

    Weber sprak van "consistente resultaten" op dit gebied en zei dat het bedrijf nu focust op een mogelijke klinische ontwikkeling van varoglutamstat bij chronische nierziekte en bepaalde zeldzame ziektes die de nierfunctie beïnvloeden.

    De studie naar Alzheimer stopt in de tweede helft van het jaar vervroegd, meldde het bedrijf al eerder. Het bedrijf kijkt nog naar resultaten bij een hogere dosis. In maart bleek dat er een cognitief effect bij Alzheimer-patiënten niet kon worden aangetoond. De aandelenkoers van Vivoryon stortte toen in.

    Vivoryon zag in het eerste kwartaal de kosten voor onderzoek en ontwikkeling stijgen van 3,1 miljoen naar 7,4 miljoen euro. Het nettoverlies steeg van 5,1 miljoen naar 9,3 miljoen euro en de kaspositie daalde van 28,6 miljoen naar 22,0 miljoen euro.

    Zoals al werd gemeld op 24 april is er voldoende geld in kas om tot het tweede kwartaal van 2025 te komen, op basis van de nieuwe plannen met focus op ontstekings- en fibrotische aandoeningen.

    Door: ABM Financial News.

    info@abmfn.nl

    Redactie: +31(0)20 26 28 999
2.637 Posts
Pagina: «« 1 ... 42 43 44 45 46 ... 132 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in
Premium

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van BeursDuivel en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 55% korting!

Word abonnee

Laatste Nieuws

  1. Inflatie en groeicijfers bepalen beursweek
  2. Delivery Hero brengt Talabat naar de beurs in Dubai
  3. Syensqo en Azelis blinken uit in Brussel
  4. Fitch positiever over Spanje
  5. Bel20 beperkt schade in roerige verkiezingsweek
  6. Consumentenprijzen China stijgen minder hard
  7. Producentenprijzen China dalen harder
  8. Wall Street scherpt records verder aan
  9. Olieprijs lager gesloten
  10. Exmar boekt meer winst
  11. Europese beurzen lager gesloten
  12. Euronext meldt hogere volumes

Meest Gelezen Premium

  1. Premium Premium
    Optietip 48: Met relatief beperkte inleg inspelen op koersherstel ASML
  2. Premium Premium
    Dividendrendement ING Groep zal oplopen tot boven de 7%
  3. Premium Premium
    ASMI komt wél met een outlookverhoging: is het aandeel koopwaardig?
  4. Premium Premium
    Vooruitblik: deze 3 zaken kunnen voor toenemende volatiliteit zorgen
  5. Premium Premium
    Adyen verliest een grote klant
  6. Premium Premium
    Zuinige marktreactie op een wederom sterke cijferset van Shell
  7. Premium Premium
    Is de koersafstraffing van Philips terecht?

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 11 november

    1. B&S Group Q3-cijfers
    2. Aperam ex €0,50 dividend
    3. ArcelorMittal ex $0,50 dividend

  2. 12 november

    1. Inflatie oktober def. (NL)
    2. Kendrion Q3-cijfers
    3. OCI Q3-cijfers
    4. TKH Q3-cijfers
    5. Bayer Q3-cijfers
    6. Infineon Q4-cijfers
    7. Renewi Q3-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda